Based on the structural and interaction similarity between the original target catechol o-methyltransferase (COMT) and the new target inhibin alpha chain (INHA), the combination of anti-Parkinson’s Disease drug tolcapone with the drug entacapone (a levodopa anti-Parkinson’s Disease enhancer) has been predicted to be effective for the treatment of MDR and XDR tuberculosis [24]. Here, COMT is linked to Parkinson disease.